Market Summary
USD291.43+0.69
Market Closed0.24%
ISRG Stock Price
ISRG RSI Chart
ISRG Valuation
ISRG Price/Sales (Trailing)
ISRG Profitability
ISRG Fundamentals
ISRG Revenue
ISRG Earnings
Price Action
52 Week Range
180.07358.07
(Low)(High)
Last 7 days
-3.0%
Last 30 days
-2.3%
Last 90 days
-12.7%
Trailing 12 Months
54.7%
ISRG Financial Health
ISRG Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ISRG
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-14 | Ladd Amy L | sold | -152,840 | 305 | -500 | - |
2023-08-07 | LEVY ALAN J | sold | -620,000 | 310 | -2,000 | - |
2023-08-07 | LEVY ALAN J | acquired | 172,074 | 86.0371 | 2,000 | - |
2023-07-31 | GUTHART GARY S | sold | -808,207 | 325 | -2,480 | ceo |
2023-07-28 | GUTHART GARY S | gifted | - | - | -16,000 | ceo |
2023-07-28 | GUTHART GARY S | sold | -16,440,700 | 326 | -50,314 | ceo |
2023-07-28 | GUTHART GARY S | acquired | 2,877,980 | 42.6367 | 67,500 | ceo |
2023-07-25 | DeSantis Robert | sold | -732,315 | 323 | -2,265 | evp & chief strategy & corp op |
2023-07-25 | DeSantis Robert | acquired | 590,185 | 232 | 2,535 | evp & chief strategy & corp op |
Which funds bought or sold ISRG recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -18.96 | 2,220,940 | 28,437,800 | 0.11% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -575,000 | - | -% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 4,835 | 19,118 | -% |
2023-09-20 | BARCLAYS PLC | added | 183 | 347,307,000 | 471,619,000 | 0.30% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -1.99 | 23,976 | 100,872 | 0.02% |
2023-09-12 | Prosperity Financial Group, Inc. | new | - | 237,990 | 237,990 | 0.21% |
2023-09-12 | Prosperity Wealth Management, Inc. | new | - | 371,005 | 371,005 | 0.24% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | reduced | -16.67 | 177 | 1,710 | -% |
2023-09-07 | Strategic Financial Concepts, LLC | added | 0.47 | 75,473 | 294,410 | 0.11% |
2023-09-07 | JAG CAPITAL MANAGEMENT, LLC | reduced | -1.91 | 7,082,950 | 29,720,400 | 3.44% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Intuitive Surgical
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 5.9% | 20,823,995 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.33% | 29,425,186 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.0% | 28,447,145 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 6.9% | 24,756,021 | SC 13G/A | |
| Feb 07, 2022 | blackrock inc. | 7.4% | 26,538,660 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 8.1% | 9,599,898 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.76% | 9,127,891 | SC 13G/A | |
| Feb 08, 2021 | fmr llc | - | 0 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.6% | 8,888,304 | SC 13G/A | |
| Feb 14, 2020 | price t rowe associates inc /md/ | 8.9% | 10,347,449 | SC 13G/A |
Recent SEC filings of Intuitive Surgical
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 15, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 29, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 14, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading |
Peers (Alternatives to Intuitive Surgical)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MDT | 104.1B | 31.6B | -3.94% | -2.93% | 28.69 | 3.3 | 1.57% | -30.40% |
ISRG | 102.4B | 6.7B | -2.29% | 54.71% | 71.85 | 15.36 | 11.75% | -0.66% |
SYK | 101.2B | 19.5B | -1.64% | 35.04% | 37.36 | 5.2 | 10.36% | 30.30% |
BDX | 71.3B | 19.0B | -6.81% | 13.51% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.6B | 5.7B | -7.61% | -15.82% | 30.67 | 7.53 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.2B | 937.8M | -2.31% | 34.57% | 316.65 | 9.84 | 16.30% | 250.21% |
SWAV | 7.3B | 616.6M | -8.54% | -23.02% | 30.01 | 11.87 | 69.52% | 343.68% |
GMED | 5.0B | 1.1B | -9.61% | -15.17% | 23.85 | 4.57 | 12.63% | 50.85% |
IRTC | 2.8B | 452.1M | -18.56% | -28.66% | -28.09 | 6.17 | 24.99% | 24.09% |
TNDM | 1.4B | 790.3M | -22.43% | -53.70% | -6.03 | 1.71 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
AVNS | 955.9M | 780.7M | -5.52% | -6.22% | -26.55 | 1.22 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
BLFS | 610.4M | 162.2M | 25.64% | -36.45% | -7.26 | 3.76 | 9.71% | 12.37% |
SILK | 590.7M | 162.9M | -22.30% | -62.37% | -11.17 | 3.63 | 42.67% | 12.82% |
Intuitive Surgical News
Returns for ISRG
Cumulative Returns on ISRG
21.7%
10-Year Cumulative Returns
20.2%
7-Year Cumulative Returns
8.9%
5-Year Cumulative Returns
9.0%
3-Year Cumulative Returns
Risks for ISRG
What is the probability of a big loss on ISRG?
76.2%
Probability that Intuitive Surgical stock will be more than 20% underwater in next one year
38.1%
Probability that Intuitive Surgical stock will be more than 30% underwater in next one year.
17.3%
Probability that Intuitive Surgical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ISRG drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Intuitive Surgical was unfortunately bought at previous high price.
Drawdowns
Financials for Intuitive Surgical
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 3.6% | 6,665 | 6,431 | 6,222 | 6,118 | 5,964 | 5,906 | 5,710 | 5,489 | 5,163 | 4,551 | 4,358 | 4,307 | 4,358 | 4,604 | 4,479 | 4,247 | 4,040 | 3,850 | 3,724 | 3,570 | 3,457 |
| Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,029 |
| Gross Profit | 3.5% | 4,448 | 4,299 | 4,196 | 4,146 | 4,065 | 4,066 | 3,959 | 3,794 | 3,546 | 3,026 | 2,861 | 2,861 | 2,923 | 3,179 | 3,110 | 2,950 | 2,807 | 2,680 | 2,604 | 2,502 | 2,428 |
| Operating Expenses | 3.0% | 2,826 | 2,743 | 2,619 | 2,491 | 2,367 | 2,253 | 2,138 | 2,007 | 1,932 | 1,842 | 1,811 | 1,830 | 1,796 | 1,774 | 1,736 | 1,641 | 1,550 | 1,505 | 1,405 | 1,306 | 1,265 |
| S&GA Expenses | 2.5% | 1,875 | 1,829 | 1,740 | 1,673 | 1,600 | 1,532 | 1,467 | 1,370 | 1,305 | 1,234 | 1,216 | 1,228 | 1,213 | 1,213 | 1,178 | 1,120 | 1,058 | 1,038 | 987 | 921 | 903 |
| R&D Expenses | 4.1% | 951 | 913 | 879 | 818 | 767 | 722 | 671 | 637 | 627 | 608 | 595 | 602 | 583 | 560 | 557 | 521 | 492 | 467 | 418 | 385 | 361 |
| EBITDA | -100.0% | - | 1,626 | 1,607 | 1,666 | 1,725 | 2,124 | 2,170 | 2,143 | 2,018 | 1,348 | 1,207 | 1,202 | 1,246 | 1,531 | 1,502 | 1,429 | 1,366 | 1,269 | - | - | - |
| EBITDA Margin | -100.0% | - | 0.25* | 0.26* | 0.27* | 0.34* | 0.36* | 0.38* | 0.39* | 0.39* | 0.30* | 0.28* | 0.28* | 0.29* | 0.33* | 0.34* | 0.34* | 0.34* | 0.33* | - | - | - |
| Earnings Before Taxes | 5.7% | 1,719 | 1,626 | 1,607 | 1,666 | 1,725 | 1,844 | 1,890 | 1,873 | 1,767 | 1,348 | 1,207 | 1,202 | 1,246 | 1,531 | 1,502 | 1,429 | 1,366 | 1,269 | 1,280 | 1,262 | 1,218 |
| EBT Margin | -100.0% | - | 0.25* | 0.26* | 0.27* | 0.34* | 0.31* | 0.33* | 0.34* | 0.34* | 0.30* | 0.28* | 0.28* | 0.29* | 0.33* | 0.34* | 0.34* | 0.34* | 0.33* | - | - | - |
| Net Income | 8.6% | 1,425 | 1,312 | 1,322 | 1,378 | 1,435 | 1,644 | 1,705 | 1,689 | 1,623 | 1,173 | 1,061 | 1,053 | 1,136 | 1,386 | 1,379 | 1,314 | 1,210 | 1,147 | 1,128 | 804 | 810 |
| Net Income Margin | -100.0% | - | 0.20* | 0.21* | 0.23* | 0.29* | 0.28* | 0.30* | 0.31* | 0.31* | 0.26* | 0.24* | 0.24* | 0.26* | 0.30* | 0.31* | 0.31* | 0.30* | 0.30* | - | - | - |
| Free Cashflow | -100.0% | - | 1,639 | 1,491 | 1,621 | 1,739 | 1,835 | 2,089 | 2,149 | 1,922 | 1,610 | 1,485 | 1,410 | 1,532 | 1,618 | 1,598 | 1,384 | 1,307 | 1,223 | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 6.5% | 13,903 | 13,053 | 12,974 | 13,261 | 13,705 | 13,678 | 13,555 | 12,935 | 12,297 | 11,540 | 11,169 | 10,618 | 10,104 | 9,891 | 9,733 | 9,131 | 8,532 | 8,235 | 7,847 | 7,319 | 6,850 |
| Current Assets | 16.8% | 8,032 | 6,877 | 6,253 | 6,293 | 6,293 | 5,803 | 5,845 | 5,728 | 6,017 | 6,066 | 6,626 | 6,300 | 5,899 | 4,692 | 4,663 | 4,317 | 4,072 | 4,025 | 4,333 | 4,253 | 3,986 |
| Cash Equivalents | 60.3% | 3,435 | 2,143 | 1,581 | 1,538 | 1,551 | 1,118 | 1,306 | 1,362 | 1,631 | 1,418 | 1,639 | 1,386 | 2,052 | 1,239 | 1,183 | 985 | 805 | 891 | 909 | 1,023 | 1,219 |
| Inventory | 6.2% | 1,005 | 947 | 893 | 837 | 724 | 653 | 587 | 585 | 570 | 577 | 602 | 663 | 646 | 620 | 596 | 580 | 513 | 468 | 409 | 370 | 332 |
| Net PPE | 9.7% | 2,831 | 2,580 | 2,374 | 2,244 | 2,109 | 1,968 | 1,876 | 1,738 | 1,651 | 1,593 | 1,577 | 1,510 | 1,450 | 1,369 | 1,273 | 1,137 | 1,032 | 935 | 812 | 746 | 689 |
| Goodwill | 0% | 349 | 349 | 349 | 348 | 349 | 343 | 344 | 344 | 344 | 345 | 337 | 336 | 337 | 335 | 307 | 305 | 245 | 248 | 6.00 | 236 | 211 |
| Liabilities | 10.5% | 1,944 | 1,759 | 1,861 | 1,687 | 1,623 | 1,522 | 1,604 | 1,475 | 1,418 | 1,350 | 1,410 | 1,331 | 1,337 | 1,361 | 1,449 | 1,354 | 1,252 | 1,195 | 1,159 | 1,030 | 980 |
| Current Liabilities | 17.7% | 1,538 | 1,307 | 1,422 | 1,233 | 1,175 | 1,112 | 1,150 | 1,027 | 1,005 | 905 | 965 | 895 | 925 | 946 | 1,030 | 931 | 808 | 740 | 821 | 703 | 666 |
| Shareholder's Equity | 5.2% | 11,879 | 11,294 | 11,042 | 11,515 | 12,082 | 12,157 | 11,952 | 11,460 | 10,880 | 10,190 | 9,759 | 9,287 | 8,766 | 8,531 | 8,285 | 7,777 | 7,280 | 7,040 | 6,688 | 6,289 | 5,869 |
| Retained Earnings | 12.1% | 3,808 | 3,397 | 3,500 | 4,018 | 4,683 | 4,858 | 4,761 | 4,390 | 4,023 | 3,515 | 3,261 | 2,937 | 2,633 | 2,571 | 2,495 | 2,143 | 1,819 | 1,696 | 1,522 | 1,234 | 948 |
| Additional Paid-In Capital | 2.8% | 8,151 | 7,928 | 7,704 | 7,685 | 7,484 | 7,355 | 7,164 | 7,015 | 6,804 | 6,627 | 6,445 | 6,304 | 6,085 | 5,927 | 5,757 | 5,601 | 5,430 | 5,329 | 5,170 | 5,063 | 4,929 |
| Accumulated Depreciation | - | - | - | 1,238 | - | - | - | 969 | - | - | - | 758 | - | - | - | 563 | - | - | - | 436 | - | - |
| Shares Outstanding | 0.3% | 351 | 350 | 350 | 353 | 358 | 358 | 358 | 357 | 356 | 354 | 353 | 352 | 350 | 349 | 348 | 346 | 346 | 345 | 344 | 342 | 341 |
| Minority Interest | 5.4% | 81.00 | 77.00 | 71.00 | 59.00 | 59.00 | 55.00 | 50.00 | 49.00 | 42.00 | 37.00 | 28.00 | 29.00 | 26.00 | 24.00 | 21.00 | 16.00 | 14.00 | 16.00 | 9.00 | 8.00 | 9.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 13.4% | 1,858 | 1,639 | 1,491 | 1,621 | 1,739 | 1,835 | 2,089 | 2,149 | 1,922 | 1,610 | 1,485 | 1,410 | 1,532 | 1,618 | 1,598 | 1,384 | 1,307 | 1,223 | 1,170 | 1,164 | 1,198 |
| Share Based Compensation | 3.7% | 552 | 532 | 513 | 503 | 485 | 467 | 449 | 435 | 420 | 408 | 395 | 382 | 365 | 350 | 336 | 317 | 298 | 280 | 261 | 246 | 232 |
| Cashflow From Investing | 4.2% | 2,250 | 2,159 | 1,371 | 155 | -1,228 | -2,079 | -2,461 | -2,154 | -2,341 | -1,420 | -940 | -1,012 | -203 | -962 | -1,154 | -1,234 | -1,590 | -1,412 | -1,049 | -879 | -566 |
| Cashflow From Financing | 19.8% | -2,208 | -2,753 | -2,572 | -1,590 | -595 | -54.70 | 43.00 | -15.40 | 2.00 | -9.20 | -85.70 | 5.00 | -79.10 | -305 | -168 | -185 | -129 | 93.00 | 126 | -150 | -124 |
| Buy Backs | -17.5% | 2,351 | 2,851 | 2,607 | 1,607 | 607 | 107 | - | 34.00 | 34.00 | 34.00 | 134 | 100 | 170 | 370 | 270 | 270 | 200 | - | - | 274 | 274 |
ISRG Income Statement
2023-06-30Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 1,755.9 | $ 1,522.1 | $ 3,452.1 | $ 3,009.8 |
| Cost of revenue: | ||||
| Total cost of revenue | 584.0 | 498.8 | 1,167.2 | 976.8 |
| Gross profit | 1,171.9 | 1,023.3 | 2,284.9 | 2,033.0 |
| Operating expenses: | ||||
| Selling, general and administrative | 464.3 | 418.4 | 944.8 | 809.5 |
| Research and development | 244.4 | 207.3 | 489.3 | 417.8 |
| Total operating expenses | 708.7 | 625.7 | 1,434.1 | 1,227.3 |
| Income from operations | 463.2 | 397.6 | 850.8 | 805.7 |
| Interest and other income, net | 36.0 | 9.3 | 70.2 | 3.6 |
| Income before taxes | 499.2 | 406.9 | 921.0 | 809.3 |
| Income tax expense | 73.2 | 93.3 | 134.2 | 126.3 |
| Net income | 426.0 | 313.6 | 786.8 | 683.0 |
| Less: net income attributable to noncontrolling interest in joint venture | 5.2 | 5.8 | 10.7 | 9.6 |
| Net income attributable to Intuitive Surgical, Inc. | $ 420.8 | $ 307.8 | $ 776.1 | $ 673.4 |
| Net income per share attributable to Intuitive Surgical, Inc.: | ||||
| Basic (in dollars per share) | $ 1.20 | $ 0.86 | $ 2.21 | $ 1.88 |
| Diluted (in dollars per share) | $ 1.18 | $ 0.85 | $ 2.18 | $ 1.84 |
| Shares used in computing net income per share attributable to Intuitive Surgical, Inc.: | ||||
| Basic (in shares) | 350.9 | 358.1 | 350.6 | 358.2 |
| Diluted (in shares) | 357.3 | 363.9 | 356.6 | 365.3 |
| Other comprehensive income (loss), net of tax: | ||||
| Unrealized gains on hedge instruments | $ 6.0 | $ 4.4 | $ 8.5 | $ 5.4 |
| Unrealized gains (losses) on available-for-sale securities | 13.1 | (33.4) | 50.7 | (124.1) |
| Foreign currency translation gains (losses) | 8.5 | (5.5) | 22.7 | (2.0) |
| Prior service cost for employee benefit plans | 0.0 | 0.0 | 0.0 | 0.1 |
| Other comprehensive income (loss) | 27.6 | (34.5) | 81.9 | (120.6) |
| Total comprehensive income | 453.6 | 279.1 | 868.7 | 562.4 |
| Less: comprehensive income attributable to noncontrolling interest | 4.1 | 4.8 | 9.9 | 9.0 |
| Total comprehensive income attributable to Intuitive Surgical, Inc. | 449.5 | 274.3 | 858.8 | 553.4 |
| Corporate Joint Venture | ||||
| Operating expenses: | ||||
| Less: net income attributable to noncontrolling interest in joint venture | 5.2 | 5.8 | 10.7 | 9.6 |
| Product | ||||
| Revenue: | ||||
| Total revenue | 1,468.6 | 1,270.4 | 2,881.6 | 2,508.8 |
| Cost of revenue: | ||||
| Total cost of revenue | 498.0 | 421.0 | 991.0 | 818.3 |
| Service | ||||
| Revenue: | ||||
| Total revenue | 287.3 | 251.7 | 570.5 | 501.0 |
| Cost of revenue: | ||||
| Total cost of revenue | $ 86.0 | $ 77.8 | $ 176.2 | $ 158.5 |
ISRG Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 3,435.4 | $ 1,581.2 |
| Short-term investments | 2,363.8 | 2,536.7 |
| Accounts receivable, net | 904.2 | 942.1 |
| Inventory | 1,005.2 | 893.2 |
| Prepaids and other current assets | 323.2 | 299.8 |
| Total current assets | 8,031.8 | 6,253.0 |
| Property, plant, and equipment, net | 2,830.8 | 2,374.2 |
| Long-term investments | 1,332.5 | 2,623.6 |
| Deferred tax assets | 666.5 | 664.6 |
| Intangible and other assets, net | 693.1 | 710.1 |
| Goodwill | 348.6 | 348.5 |
| Total assets | 13,903.3 | 12,974.0 |
| Current liabilities: | ||
| Accounts payable | 199.7 | 147.0 |
| Accrued compensation and employee benefits | 346.6 | 401.6 |
| Deferred revenue | 405.2 | 397.3 |
| Other accrued liabilities | 586.9 | 476.2 |
| Total current liabilities | 1,538.4 | 1,422.1 |
| Other long-term liabilities | 405.2 | 439.3 |
| Total liabilities | 1,943.6 | 1,861.4 |
| Contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; zero shares issued and outstanding as of June 30, 2023, and December 31, 2022 | 0.0 | 0.0 |
| Common stock, 600.0 shares authorized, $0.001 par value, 351.3 shares and 350.0 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively | 0.4 | 0.4 |
| Additional paid-in capital | 8,150.8 | 7,703.9 |
| Retained earnings | 3,807.7 | 3,500.1 |
| Accumulated other comprehensive loss | (79.8) | (162.5) |
| Total Intuitive Surgical, Inc. stockholders’ equity | 11,879.1 | 11,041.9 |
| Noncontrolling interest in joint venture | 80.6 | 70.7 |
| Total stockholders’ equity | 11,959.7 | 11,112.6 |
| Total liabilities and stockholders’ equity | $ 13,903.3 | $ 12,974.0 |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.